Aktuelle Mitteilungen & Events >> Aktuelle Mitteilungen >> Eurofins completes its testing portfolio for BioPharmaceuticals

Eurofins completes its testing portfolio for BioPharmaceuticals

Sidebar Image

Through the acquisition of PHAST GmbH, Eurofins BioPharma Product Testing has strengthened its service portfolio for the research-oriented biotech and pharmaceutical industries by offering full service testing packages for large and small molecules. Customers now benefit from a complete package of physico-chemical and microbiological tests for raw materials, finished products, APIs and excipients.  

Eurofins PHAST specializes on analytical testing and quality control for finished products as well as on analytical method development. As authorized distributor for reference standards in Europe, Eurofins PHAST adds another important service to Eurofins BioPharma Product Testing’s portfolio. Further capacities in the fields of bioassays and protein analytics as well as stability storage are rounding off the profile of the new laboratories.  

The testing portfolio of Eurofins BioPharma Product Testing in Germany encompasses an extensive range of microbiology studies for large and small molecules, offered by laboratories in Hamburg and Munich. Eurofins delivers all microbiological test systems for the quality control of raw materials, bulk, final products and holding studies as well as the validation of hygienic monitoring.  

Besides its testing portfolio Eurofins PHAST provides scientific consulting to internal and external customers for research and training. This consulting service pools the pharmaceutical expertise throughout the group. To know e.g. the procedures of licensing finished medicinal products shortens the time to market for the customers. Through their active association work all consulting experts at Eurofins PHAST are well informed about all scientific and regulatory developments.  

Headquartered in Homburg and with a further site in Constance, Eurofins PHAST has two state-of-the-art laboratory facilities. Including the existing laboratory in Hamburg as well as the recently extended campus at the Planegg site near Munich, the total laboratory and office space of the Eurofins BioPharma Product Testing Group in Germany has increased to over 20,000 sqm with more than 700 employees serving the customers.  

At the upcoming CPHI Worldwide in Madrid, Spain, Eurofins BioPharma Product Testing will present its services at stand 3G76. Please use this opportunity and visit us to discuss your needs and expectations and to learn more about our extensive service portfolio. We are looking forward to meeting you!  

If you wish to learn more about the acquisition of PHAST by Eurofins Scientific please read our press release.